vs

Side-by-side financial comparison of CITIUS ONCOLOGY, INC. (CTOR) and Metalla Royalty & Streaming Ltd. (MTA). Click either name above to swap in a different company.

CITIUS ONCOLOGY, INC. is the larger business by last-quarter revenue ($3.9M vs $3.8M, roughly 1.1× Metalla Royalty & Streaming Ltd.). Metalla Royalty & Streaming Ltd. runs the higher net margin — -117.1% vs -140.3%, a 23.3% gap on every dollar of revenue.

Citius Oncology, Inc. is a late-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its core pipeline covers treatments addressing unmet medical needs in hematologic malignancies and solid tumors, primarily serving North American and global oncology care markets.

Metalla Royalty & Streaming Ltd. is a precious metals royalty and streaming firm focused on gold, silver, and strategic mineral assets primarily across North America. It partners with mining operators to earn stable, leveraged returns without incurring the high costs and operational risks of direct mine ownership, catering to investors seeking low-volatility exposure to precious metals markets.

CTOR vs MTA — Head-to-Head

Bigger by revenue
CTOR
CTOR
1.1× larger
CTOR
$3.9M
$3.8M
MTA
Higher net margin
MTA
MTA
23.3% more per $
MTA
-117.1%
-140.3%
CTOR

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
CTOR
CTOR
MTA
MTA
Revenue
$3.9M
$3.8M
Net Profit
$-5.5M
$-4.4M
Gross Margin
80.0%
50.4%
Operating Margin
-133.2%
Net Margin
-140.3%
-117.1%
Revenue YoY
Net Profit YoY
16.9%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTOR
CTOR
MTA
MTA
Q4 25
$3.9M
Q3 25
$3.8M
Q2 25
$2.1M
Q1 25
$1.3M
Q3 24
$3.3M
Q1 24
$981.0K
Net Profit
CTOR
CTOR
MTA
MTA
Q4 25
$-5.5M
Q3 25
$-4.4M
Q2 25
$-3.2M
Q1 25
$-1.7M
Q3 24
$-4.0M
Q1 24
$-1.4M
Gross Margin
CTOR
CTOR
MTA
MTA
Q4 25
80.0%
Q3 25
50.4%
Q2 25
39.7%
Q1 25
39.2%
Q3 24
48.5%
Q1 24
59.3%
Operating Margin
CTOR
CTOR
MTA
MTA
Q4 25
-133.2%
Q3 25
Q2 25
Q1 25
-102.5%
Q3 24
-176.4%
Q1 24
-121.5%
Net Margin
CTOR
CTOR
MTA
MTA
Q4 25
-140.3%
Q3 25
-117.1%
Q2 25
-151.3%
Q1 25
-138.0%
Q3 24
-120.3%
Q1 24
-138.2%
EPS (diluted)
CTOR
CTOR
MTA
MTA
Q4 25
$-0.06
Q3 25
Q2 25
Q1 25
Q3 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTOR
CTOR
MTA
MTA
Cash + ST InvestmentsLiquidity on hand
$7.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$58.4M
Total Assets
$110.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTOR
CTOR
MTA
MTA
Q4 25
$7.3M
Q3 25
Q2 25
Q1 25
Q3 24
Q1 24
Stockholders' Equity
CTOR
CTOR
MTA
MTA
Q4 25
$58.4M
Q3 25
Q2 25
Q1 25
Q3 24
Q1 24
Total Assets
CTOR
CTOR
MTA
MTA
Q4 25
$110.0M
Q3 25
Q2 25
Q1 25
Q3 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTOR
CTOR
MTA
MTA
Operating Cash FlowLast quarter
$-7.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTOR
CTOR
MTA
MTA
Q4 25
$-7.4M
Q3 25
Q2 25
Q1 25
Q3 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons